← SynDRA
KW-2449
SynDRA canonical compound SYN0028187 — structure-anchored drug synonym record
Clinical phase
Phase 1
Primary target(s)
ABL1 | AURKA | AURKB | FGFR1 | FLT3
Mechanism of action
Abl kinase inhibitor | Aurora kinase inhibitor | FLT3 inhibitor
All known targets
ABL1
FLT3
AURKA
AURKB
FGFR1
Mechanisms of action (all sources)
AURKA INHIBITOR
Serine/threonine-protein kinase Aurora-A inhibitor
AURKB INHIBITOR
Serine/threonine-protein kinase Aurora-B inhibitor
FLT3 INHIBITOR
Tyrosine-protein kinase receptor FLT3 inhibitor
ABL1 INHIBITOR
Tyrosine-protein kinase ABL inhibitor
Abl kinase inhibitor
aurora kinase inhibitor
Cross-references
PubChem CID:
11427553
ChEMBL:
CHEMBL1908397
ChEBI:
91441
TTD: D00ABO
Synonyms
Tumor antigen-specific mAb (cancer), Kyowa
Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin
Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo
KW2449
UNII-2D9N67F58G
KW 2449 [WHO-DD]
Piperazine, 1-(4-((1E)-2-(1H-indazol-3-yl)ethenyl)benzoyl)-
RefChem:151583
FLT3/ABL/AURORA KINASE INHIBITOR KW-2449
MFCD18385006
2D9N67F58G
1-[4-[(1E)-2-(1H-Indazol-3-yl)ethenyl]benzoyl]piperazine
3-{2-[4-(PIPERAZINE-1-CARBONYL)PHENYL]ETHENYL}-1H-INDAZOLE
YYLKKYCXAOBSRM-JXMROGBWSA-N
KW-2449 Hydrochloride?
orb15754
MLS006011271
GTPL5691
SCHEMBL1596894
SCHEMBL29356539
CHEBI:91441
GLXC-05879
EX-A2306
BDBM50355496
NSC759675
NSC800778
s2158
AKOS027460993
CCG-267833
CS-0231
NSC-759675
NSC-800778
SDCCGSBI-0654393.P001
NCGC00346569-05
NCGC00346569-07
AC-28419
AS-71712
FI153964
Look up KW-2449 in the interactive SynDRA portal →